| Literature DB >> 29971010 |
Jane Hejlesen1, Line Underbjerg2, Hans Gjørup3, Agnes Bloch-Zupan4,5,6, Tanja Sikjaer2, Lars Rejnmark2, Dorte Haubek1.
Abstract
Background: Dental aberrations have been mentioned in relation to non-surgical hypoparathyroidism (Ns-HypoPT) and pseudohypoparathyroidism (PHP). However, a systematic review of dental characteristics have not been performed. The present systematic review describes the dental findings in patients with Ns-HypoPT and PHP.Entities:
Keywords: 22q11 deletion syndrome; dental anomalies; enamel hypoplasia; hypoparathyroidism; pseudohypoparathyroidism
Year: 2018 PMID: 29971010 PMCID: PMC6018410 DOI: 10.3389/fphys.2018.00701
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
Classification of genetic and autoimmune causes of hypoparathyroidism.
| PTH biosynthesis/secretion | |
| Familial isolated hypoparathyroidism, autosomal recessive (chromosome 6p24.2, | 146200 |
| Hypoparathyroidism, autosomal recessive (chromosome 11p15.3, | 146200 |
| Hypoparathyroidism, autosomal dominant (chromosome 11p15.3, | 146200 |
| Calcium Sensing Receptor ( | |
| Autosomal Dominant Hypocalcemia, ADH (chromosom 13q13.3-q21.1, | 601198 |
| Autosomal Dominant Hypocalcemia with Bartters syndrome, ADH (chromosom 13q13.3-q21.1, | 601198 |
| Parathyroid development | |
| 22q11 deletion (chromosome 22q11, | 188400 |
| Hypoparathyroidism, retardation and dysmorphism syndrome, HRDS (chromosome 1q42.3) | 241410 |
| Sanjad Sakati Syndrome | |
| Kenney-Caffey syndrome 1 and 2. Arab descent | 244460 |
| Hypoparathyroidism, sensorineural deafness and renal disease, HDR (chromosome 10p14) | 142655 |
| Familial isolated hypoparathyroidism, autosomal recessive (chromosome 6p24.2, | 146200 |
| Hypoparathyroidism, X-linked, HYPX (chromosome Xq26-q27) | 307700 |
| Mitochondrial disease | |
| Kears-Sayre syndrome, KSS | 530000 |
| Pearson Marrow-Pancreas Syndrome | 557000 |
| Mitochondrial myopathy, encephalopathy., lactic acidosis and stroke-like episodes, MELAS | 540000 |
| Mitochondrial trifunctional Protein Deficiency, MTPD | 609015 |
| Diabetes and Deafness, Maternally Inherited, MIDD | 520000 |
| Autoimmune | |
| Autoimmune Polyglandular Syndrome type 1, APS-1 | 240300 |
| Autoimmune Polyendocrinopthy-candidiasis-esctodermal dystrophy, APECED (chromosome 21q22.3, | 607358 |
| Anti-CaSR antibodies |
Figure 1Search string used for the establishment of the study material.
Figure 2Flowchart illustrating the extraction of publications for the present review.
Characteristics of studies on patients with non-surgical hypoparathyroidism.
| Jensen et al., | Case series | 5 | 29 [12–67] | 1/4 | Denmark | 0 (0) | 1, 2, 3 | 5 |
| Kelly et al., | Case report | 1 | 9 | 0/1 | Brazil | 0 (0) | 1, 2, 3 | 1 |
| Lyles et al., | Case report | 1 | 25 | 1/0 | USA | 0 (0) | 1, 2 | 1 |
| Moshkowitz et al., | Case report | 1 | 10 | 0/1 | Israel | 0 (0) | 1, 2, 4 | 1 |
| Assif, | Case report | 1 | 15.5 | 1/0 | Israel | 0 (0) | 1, 2 | – |
| Frensilli et al., | Case series | 3 | 26 [17–42] | 2/1 | USA | 0 (0) | 1, 2, 4 | 3 |
| Kamarthi et al., | Case report | 1 | 22 | 1/0 | India | 0 (0) | 1, 2, 3 | 1 |
| Srirangarajan et al., | Case report | 1 | 40 | 0/1 | India | 0 (0) | 1, 3 | 1 |
| Lindeberg, | Case report | 1 | 16 | 0/1 | Denmark | 0 (0) | 1, 2, 3 | 1 |
| Lovestedt, | Case report | 1 | 14 | 0/1 | USA | 0 (0) | – | – |
| Illum et al., | Case series | 11* | 41 [12–67] | 4/7 | Denmark | 0 (0) | 1, 2, 3 (3/11) | 5 |
| Harrell, | Case report | 1 | 27 | 1/0 | England | 0 (0) | 1, 3 | 1 |
| Nortjé, | Case report | 1 | 22 | 0/1 | South Africa | 0 (0) | 1, 2 | – |
| Pisanty, | Case report | 1 | 10 | 0/1 | Persian | 0 (0) | 1, 2, 4 | 1 |
| Riley, | Case series | 2 | 13 [13-13] | 0/2 | USA | 0 (0) | 1, 2, 4 | 2 |
| Nikiforuk and Fraser, | Case series | 17 | < 18 | – | Canada | 0 (0) | 1, 2 | 17 |
| Myllärniemi and Perheentupa, | Case series | 3 | 12 [2-22] | 0/3 | Finland | 0 (0) | – | 3 |
| de Carvalho et al., | Case report | 1 | 45 | 1/0 | Denmark | 0 (0) | 1, 2, 3 | 1 |
| Hansted and Holst, | Case report | 1 | 19 | 0/1 | Denmark | 0 (0) | – | – |
| Humphreys, | Case report | 1 | 23 | 0/1 | England | 0 (0) | 1, 4 | 1 |
| Nally, | Case report | 1 | 13 | 0/1 | England | 0 (0) | 1 | – |
| Hinrichs, | Case series | 5 | 12 [6-18] | 3/2 | USA | 0 (0) | 1, 2, 4 (1/5) | 1 |
| Thew and Goulston, | Case report | 1 | 27 | 1/0 | Australia | 0 (0) | 1,4 | 1 |
| Mohsenipour et al., | Case series | 12 | < 18 | – | Iran | 0 (0) | – | – |
| Sjöberg, | Case series | 3 | 22 [18–25] | 1/2 | Sweden | 0 (0) | 1, 2, 4 | 1 |
| Subtotal | 77 | 48 | ||||||
| Goepferd and Flaitz, | Case report | 1 | 14 | 0/1 | USA | 0 (0) | 1, 2,4 | 1 |
| Ingemarsson, | Case report | 1 | 6 | 0/1 | Denmark | 0 (0) | 1, 2, 3 | 1 |
| Subtotal | 2 | 2 | ||||||
| Klingberg et al., | Cross-sectional | 29 | 12 [2–36] | 13/16 | Sweden | 0 (0) | – | 6 |
| Lewyllie et al., | Cross-sectional | 20 | 9 [5–14] | 12/8 | Belgium | 0 (0) | – | – |
| Toka et al., | Case series | 5 | 12 [6–15] | 3/2 | Germany | 0 (0) | 1 (1/5), 3 (1/5) | 2 |
| Heliövaara et al., | Cross-sectional | 45 | 8 [6–13] | 22/23 | Finland | 45 (45) | – | – |
| Nordgarden et al., | Cross-sectional | 50 | 10 [2–44] | 23/27 | Norway | 50 (50) | – | 12 |
| Matthews-Brzozowska et al., | Case report | 1 | 7 | 1/0 | Poland | 1 (1) | – | – |
| Børglum Jensen et al., | Case report | 1 | 8 | 0/1 | Denmark | 1 (1) | 1, 2, 4 | 1 |
| Fukui et al., | Case series | 2 | 13;13 | 2/0 | Japan | 2 (1) | 1 (2/2), 4 (1/2) | 2 |
| Klingberg et al., | Cross-sectional | 53 | 11 [3–43] | 23/30 | Sweden | 0 (0) | 3 (9/53) | 9 |
| da Silva Dalben et al., | Case series | 26 | 18 [7–48] | 11/15 | Brazil | 0 (0) | – | – |
| Oberoi et al., | Cross-sectional | 56 | [3–14] | 27/29 | USA | 0 (0) | – | – |
| Laccetta et al., | Case report | 1 | 5 | 1/0 | Italy | 1 (1) | – | – |
| Klingberg et al., | Case series | 15 | 11 [5-19] | – | Sweden | 0 (0) | 1 (7/15) | 7 |
| Yang et al., | Case report | 1 | 23 | 0/1 | Taiwan | 1 (1) | 1, 2 | *** |
| Oberoi and Vargervik, | Case series | 3 | 9 [6–12] | 1/2 | USA | 3 (3) | – | – |
| Jaquez et al., | Case report | 1 | 8 | 0/1 | USA | 1 (1) | – | – |
| Subtotal | 309 | 39 | ||||||
| Greenberg et al., | Case report | 1 | 16 | 1/0 | USA | 0 (0) | 1, 2, 4 | 1 |
| Pisanty and Garfunkel, | Case series | 6 | 19 [10–30] | 3/3 | Israel/Persian | 0 (0) | – | 6 |
| Hermans et al., | Case series | 3 | 27 [25–29] | 1/2 | USA | 0 (0) | 1 (1/3), 2 (1/3) | 1 |
| Kollios et al., | Case report | 1 | 11 | 0/1 | Switzerland | 1 (1) | 1, 2 | 1 |
| Perniola et al., | Case series | 4 | 15 [9–20] | 2/2 | Italy | 0 (0) | – | 3 |
| Ahonen et al., | Cross-sectional | 68** | [1-60] | – | Finland | 0 (0) | – | 54 |
| Bruserud et al., | Cross-sectional | 52 | 9 [0-43] | 28/24 | Norway | 52 (52) | – | 38 |
| López-Jornet et al., | Case report | 1 | 10 | 0/1 | Spain | 0 (0) | 1, 2, 3 | 1 |
| Myllärniemi and Perheentupa, | Case series | 29 | [4–28] | 10/19 | Finland | 0 (0) | – | – |
| Lukinmaa et al., | Case series | 3 | 21 [17–26] | 3/0 | Finland | 0 (0) | – | 2 |
| McGovern et al., | Cross-sectional | 16 | 13 [2–39] | 7/9 | Ireland | 16 (16) | – | 13 |
| Ponranjini et al., | Case report | 1 | 35 | 0/1 | India | 0 (0) | 1, 2, 3 | 1 |
| Ferre et al., | Prospective | 35 | 20 [7–64] | 14/21 | North/South America | 35 (35) | – | 30 |
| Bjanid et al., | Case report | 1 | 14 | 0/1 | Poland | 0 (0) | 1, 2, 3 | 1 |
| Porter et al., | Case report | 1 | 7 | 0/1 | England | 0 (0) | 1, 2, 3 | 1 |
| Walls and Soames, | Case series | 2 | 20 [19–21] | 0/2 | England | 0 (0) | – | 2 |
| Porter et al., | Case report | 1 | 17 | 1/0 | England | 0 (0) | 1, 3 | – |
| Firth et al., | Case report | 1 | 21 | 0/1 | Australia | 0 (0) | – | 1 |
| Porter and Scully, | Case series | 2 | 30; − | 1/1 | England | 0 (0) | – | 1 |
| Ali et al., | Case report | 1 | 15 | 1/0 | Bangladesh | 0 (0) | 1, 3 | 1 |
| Winer and Merke, | Case report | 1 | 10 | 1/0 | USA | 0 (0) | – | – |
| Pavlic and Waltimo-Siren, | Case series | 3 | 3 [9–15] | 1/2 | Slovenia | 3 (3) | – | – |
| Subtotal | 233 | 158 | ||||||
| Al-Malik, | Case report | 1 | 4 | 0/1 | Saudi | 0 (0) | 1, 2, 3 | 1 |
| Wasersprung et al., | Case report | 1 | 12 | 1/0 | Bedouin origin | 0 (0) | – | – |
| El Batawi, | Case report | 1 | 4 | 1/0 | Saudi Arabia | 0 (0) | 1 | – |
| Hershkovitz et al., | Case series | 6 | 2 [0–3] | 3/3 | Arab | 0 (0) | 1, 2, 3 | 6 |
| Subtotal | 9 | 7 | ||||||
| Total | 630 (603****) | 254 | ||||||
–, No data reported,
Only nine patients had oral examination preformed.
The remaining two patients had no teeth,
Only 43 had oral examination,
Hypocalcemia, but normal PTH level 2,711 pg/ml,
603 patients had oral examination performed.
Biochemical tests carried out: 1: low calcium serum concentration, 2: high phosphate concentration, 3: low serum parathyroid hormone (PTH), 4: a rise in the plasma calcium concentration or/and a drop in plasma phosphate concentration in response to the injection of parathyroid hormone, 5: high PTH level, 6: PTH level and thyroid function test.
Hypo-PT, hypoparathyroidism.
Reporting of oro-dental findings in patients with non-surgical hypoparathyroidism.
| Jensen et al., | (1/5) | (1/5) | Reduced (1/5) normal (4/5) | 1 (2/5), 2 (4/5) | (3/5) | (1/5) | (1/5) | – | – |
| Kelly et al., | (1/1) | (1/1) | Reduced | 1 (1/1) | – | (1/1) | (1/1) | – | – |
| Lyles et al., | – | (1/1) | – | – | – | – | – | (1/1) | - |
| Moshkowitz et al., | (1/1) | (1/1) | – | – | – | – | – | – | – |
| Assif, | – | (1/1) | – | 1 (1/1), 3 (1/1) | – | (1/1) | (1/1) | (1/1) | – |
| Frensilli et al., | – | (3/3) | – | 3 (1/3) | – | (3/3) | – | (1/3) | – |
| Kamarthi et al., | – | (1/1) | Reduced (microdontia) | 2 (1/1) | – | (1/1) | – | (1/1) | – |
| Srirangarajan et al., | – | – | – | – | – | (1/1) | – | – | – |
| Lindeberg, | – | – | Reduced (peg shaped) | – | (1/1) | – | – | – | – |
| Lovestedt, | – | (1/1)** | – | – | – | – | – | – | – |
| Illum et al., | – | (3/9) | – | 1 (1/9), 3 (3/9) | (4/9) | (3/9) | – | – | – |
| Harrell, | – | (1/1) | – | – | – | – | – | – | – |
| Nortjé, | – | (1/1) | – | 2 (1/1) | – | (1/1) | – | – | – |
| Pisanty, | (1/1) | (1/1) | – | – | – | – | – | – | – |
| Riley, | – | (2/2) | – | 1 (1/2) | – | (1/2) | – | – | – |
| Nikiforuk and Fraser, | – | (14/17) | – | – | – | – | – | (0/17) | – |
| Myllärniemi and Perheentupa, | – | None | – | – | – | – | – | – | – |
| de Carvalho et al., | – | – | – | None | – | – | – | – | – |
| Hansted and Holst, | – | (1/1) | – | 3 (1/1) | (1/1) | - | - | (1/1) | – |
| Humphreys, | – | (1/1) | – | – | – | – | – | – | – |
| Nally, | – | (1/1) | – | – | (1/1) | – | – | – | – |
| Hinrichs, | – | (3/5) | Normal (1/5) | 1 (1/5), 2 (1/5), 3 (1/5) | (2/5) | (2/5) | – | (4/5) | – |
| Thew and Goulston, | – | – | Reduced (microdontia) | – | (1/1) | (1/1) | – | (1/1) | – |
| Mohsenipour et al., | – | (6/12) | – | 1 (4/12) | – | – | – | (4/12) | – |
| Sjöberg, | – | (2/3) | – | – | – | – | – | – | – |
| Subtotal | 4 | 46 | 1 (11), 2 (7), 3 (7) | 13 | 16 | 3 | 14 | 0 | |
| Goepferd and Flaitz, | – | (1/1) | – | 1 (1/1) | – | (1/1) | – | – | – |
| Ingemarsson, | (1/1) | (1/1) | – | 1 (1/1) | * | – | – | – | – |
| Subtotal | 1 | 2 | 1 (2) | 0 | 1 | 0 | 0 | 0 | |
| Klingberg et al., | (11/29) | (8/29) | – | – | (5/29) | – | – | – | – |
| Lewyllie et al., | – | (2/20) | – | 2 (3/20) | (4/20) | – | – | – | – |
| Toka et al., | (2/5) | (3/5) | Reduced (1/5) | 1 (1/5) | – | – | – | – | – |
| Heliövaara et al., | – | – | – | None | (8/45) | – | – | – | – |
| Nordgarden et al., | (29/50) | (21/50) | – | – | (6/40) | – | – | – | – |
| Matthews-Brzozowska et al., | – | – | – | 1 (1/1) | none | – | – | – | – |
| Børglum Jensen et al., | – | (1/1) | – | – | – | – | – | – | – |
| Fukui et al., | (1/2) | (2/2) | – | 1 (2/2) | (2/2) | – | – | – | – |
| Klingberg et al., | (23/53) | (16/53) | Reduced (peg shaped) (8/53) | 1 (9/53) | (7/53) | – | – | – | – |
| da Silva Dalben et al., | (15/26) | (4/26) | Extra cusp (4/26) missing cusp (9/26) reduced (microdontia) (2/26) | – | (6/26) | – | – | – | – |
| Oberoi et al., | – | – | – | 1 (9/56) | (7/56) | – | – | – | – |
| Laccetta et al., | – | (1/1) | – | – | – | – | – | – | – |
| Klingberg et al., | (11/15) | (5/15) | – | – | – | – | – | – | – |
| Yang et al., | – | – | – | – | – | – | – | – | (1/1) |
| Oberoi and Vargervik, | (0/3) | (0/3) | Normal | None | (2/3) | None | None | None | (1/3) |
| Jaquez et al., | – | – | – | – | – | – | – | – | – |
| Subtotal | 92 | 63 | 1 (22), 2 (3) | 53 | 0 | 0 | 0 | 2 | |
| Greenberg et al., | – | (1/1) | – | – | 4 | 1 | – | – | – |
| Pisanty and Garfunkel, | – | (2/6) | – | 2 (2/6) | (2/6) | (6/6) | – | (4/6) | - |
| Hermans et al., | – | (1/3) | – | – | – | – | – | – | – |
| Kollios et al., | – | (1/1) | – | – | – | – | – | – | – |
| Perniola et al., | – | (4/4) | – | – | – | – | – | – | – |
| Ahonen et al., | – | (33/43) | – | – | – | – | – | – | – |
| Bruserud et al., | (5/31) | (18/31) | – | – | – | – | – | – | – |
| López-Jornet et al., | – | (1/1) | – | – | – | – | – | – | – |
| Myllärniemi and Perheentupa, | – | (23/29) | – | 3 (3/29) | – | (0/29) | – | – | – |
| Lukinmaa et al., | – | (3/3) | – | – | – | – | – | – | – |
| McGovern et al., | (10/16) | (10/16) | – | – | – | – | – | – | – |
| Ponranjini et al., | – | (1/1) | – | 1 (1/1), 2 (1/1) | – | (1/1) | – | – | – |
| Ferre et al., | – | (30/35) | – | – | – | – | – | – | – |
| Bjanid et al., | – | (1/1) | – | – | – | – | – | – | – |
| Porter et al., | – | (1/1) | – | – | – | – | – | – | – |
| Walls and Soames, | (2/2) | (2/2) | – | 3 (1/2) | – | – | – | – | – |
| Porter et al., | – | (1/1) | – | – | – | – | – | – | – |
| Firth et al., | – | (1/1) | – | – | – | – | – | – | – |
| Porter and Scully, | – | (2/2) | – | – | – | – | – | – | – |
| Ali et al., | – | (1/1) | – | – | – | – | – | – | – |
| Winer and Merke, | – | (1/1) | – | – | – | – | – | – | – |
| Pavlic and Waltimo-Siren, | (1/3) | (3/3) | – | 1 (1/3) | – | – | – | – | – |
| Subtotal | 17 | 139 | 1 (2), 2 (3), 3 (4) | 6 | 8 | 0 | 4 | 0 | |
| Al-Malik, | – | (1/1) | Reduced (microdontia) | – | – | – | – | – | – |
| Wasersprung et al., | – | - | Reduced (microdontia) | 1 (1/1) | (1/1) | – | – | (1/1) | – |
| El Batawi, | – | – | Reduced (microdontia) | – | – | – | – | – | – |
| Hershkovitz et al., | – | – | – | 1 (****/6) | – | – | – | – | – |
| Subtotal | 0 | 1 | 1 (1+****) | 1 | 0 | 0 | 1 | 0 | |
| Total | 115 | 251 | 1 (38+****), 2 (13), 3 (11) | 73 | 25 | 3 | 19 | 4 | |
–, No data reported.
Too early to diagnose aplasia for the missing 15.
>Pitting seen in clinical photos in the publication.
De Carvalho study only reported denture and no impacted teeth.
Reported as a common abnormality, however, did not report the exact no. of patient.
Eruption disturbances: 1: delayed eruption, 2: impaction, 3: retention.
Root deviations: Short root and/or thin root and/or incomplete root formation.
Pulp deviations: Widened and/or calcification of pulp.
SMCI, Single maxillary central incisor.
Characteristics of studies on patients with pseudohypoparathyroidism.
| Jensen et al., | Case series | 6 | 24 [10–47] | 3/3 | Denmark | PHP | 0 (0) | 1, 2, 3 |
| Okano et al., | Case report | 1 | 22 | 1/0 | Japan | PHP | 0 (0) | 6 |
| Ritchie, | Case series | 4 | 19 [10–24] | 1/3 | England | PHP | 0 (0) | – |
| Croft et al., | Case report | 1 | 12 | 0/1 | Brazil | PHP | 0 (0) | 1, 2, 6 |
| Cohen, | Case report | 1 | 21 | 1/0 | USA | PHP | 0 (0) | – |
| Illum et al., | Case series | 6 | 24 [10–47] | 3/3 | Denmark | PHP | 0 (0) | 1, 5 |
| Witkop, | Case report | 1 | 12 | 0/1 | – | PHP | 0 (0) | – |
| Myllärniemi and Perheentupa, | Case series | 2 | 11 [9-14] | 1/1 | Finland | PHP | 0 (0) | – |
| Nikiforuk and Fraser, | Case series | 4 | < 18 | – | Canada | PHP | 0 (0) | 1, 2 |
| Lagarde et al., | Case report | 1 | 17 | – | France | PHP | 0 (0) | – |
| Glynne et al., | Case report | 1 | 32 | 0/1 | Scotland | PHP | 0 (0) | 1, 6 |
| Storm et al., | Case report | 1 | 3 | 0/1 | Denmark | PPHP | 0 (0) | – |
| Velez et al., | Case report | 1 | 14 | 0/1 | African American | AHO | 0 (0) | 1 |
| Gomes et al., | Case report | 1 | 17 | 0/1 | Brazil | AHO | 1 (1) | 1, 2 |
| Hugar et al., | Case report | 1 | 32 | 1/0 | India | AHO | 0 (0) | 1, 6 |
| Goswami et al., | Case report | 1 | 13 | 0/1 | India | AHO | 0 (0) | 1, 2 |
| Brown and Aaron, | Case report | 1 | 14 | 1/0 | USA | AHO | 0 (0) | 1 |
| Sengupta et al., | Case report | 1 | 16 | 0/1 | India | AHO | 0 (0) | 1, 2, 5 |
| Delantoni et al., | Case report | 1 | 28 | 1/0 | Greece | Type 1a | 0 (0) | 1, 2 |
| Reis et al., | Case series | 6 | 23 [8–32] | 3/3 | Brazil | AHO | 6 (6) | – |
| Reis et al., | Case series | 13 | 29 [10–48] | 7/6 | Brazil | Type 2b | 13 (13) | – |
| Gallacher et al., | Case report | 1 | 23 | 1/0 | United Kingdom | Type 1b | 1 (1) | 1, 5 |
| Total | 56 | |||||||
–, No data reported.
Biochemical test carried out: 1: low calcium serum concentration, 2: high phosphate concentration, 3: low serum parathyroid hormone (PTH), 4: a rise in the plasma calcium concentration or/and a drop in plasma phosphate concentration in response to the injection of parathyroid hormone, 5: high PTH level, 6: PTH level and thyroid function test.
Reporting of oro-dental findings in patients with pseudohypoparathyroidism.
| Jensen et al., | (1/6) | (5/6) | Normal | 1 (3/6), 2 (3/6) | (4/6) | (2/6) | (4/6) | (1/6) | Thickening (1/6) |
| Okano et al., | – | (1/1) | – | 3 (1/1) | (1/1) | – | – | – | – |
| Ritchie, | – | (3/4) | Reduced (2/4) | 1 (1/4), 3 (1/4) | (2/4) | (2/4) | (1/4) | (3/4) | – |
| Croft et al., | (0/1) | (1/1) | Normal | 3 (1/1) | (1/1) | – | – | (1/1) | – |
| Cohen, | – | (1/1) | – | – | – | (1/1) | (1/1) | – | – |
| Illum et al., | – | (6/6) | - | 1 (?*/6) | (?/6) | (?/6) | – | – | – |
| Witkop, | – | (1/1) | Reduced (peg shaped) | 1 (1/1) | (0/1) | (1/1) | – | (1/1) | – |
| Myllärniemi and Perheentupa, | – | (0/2) | – | – | – | – | – | – | – |
| Nikiforuk and Fraser, | – | (1/4) | – | – | – | – | – | (0/4) | – |
| Lagarde et al., | – | (1/1) | Normal | – | (1/1) | (0/1) | – | (1/1) | – |
| Glynne et al., | – | (1/1) | – | 3 (1/1) | – | (1/1) | (1/1) | – | – |
| Storm et al., | – | (1/1) | – | None | – | – | – | – | – |
| Velez et al., | – | (1/1) | – | 2 (1/1) | – | (1/1) | – | (1/1) | Thickening (1/1) |
| Gomes et al., | – | (0/1) | – | None | – | (0/1) | – | – | – |
| Hugar et al., | – | (1/1) | – | 2 (1/1) | (1/1) | – | – | (1/1) | Loss of lamina dura |
| Goswami et al., | – | (1/1) | – | 1 (1/1) | – | – | – | – | – |
| Brown and Aaron, | – | (1/1) | Reduced (microdontia) | 1 (1/1) | (1/1) | – | – | (1/1) | – |
| Sengupta et al., | – | (1/1) | – | – | (1/1) | – | – | – | – |
| Delantoni et al., | – | (1/1) | – | 2 (1/1) | – | (1/1) | (1/1) | – | – |
| Reis et al., | – | (5/6) | – | 3 (3/6) | none | (5/6) | (5/6) | (1/6) | – |
| Reis et al., | – | (7/13) | – | 3 (6/13) | (1/13) | (7/13) | (7/13) | (3/13) | – |
| Gallacher et al., | – | (1/1) | Normal | 3 (1/1) | (0/1) | (1/1) | (1/1) | (0/1) | (0/1) |
| Total | 1 | 41 | 1 (8+?), 2 (5), 3 (14) | 13+? | 22+? | 21 | 14 | ||
–, No data reported.
Reported as a common abnormality, however, did not report the exact no. of patient.
Eruption disturbances: 1: delayed eruption, 2: impaction, 3: retention.
Pulp deviations: Widened and/or calcification of pulp.
Root deviations: Short root and/or thin root and/or incomplete root formation.
Quality assessment using the Newcastle-Ottawa Scale.
| Klingberg et al. | Sweden | Cross-sectional | * | * | * | 3 | ||||||||
| Lewyllie et al. | Belgium | Cross-sectional | * | * | 2 | |||||||||
| Heliövaara et al. | Finland | Cross-sectional | * | * | 2 | |||||||||
| Nordgarden et al. | Norway | Cross-sectional | * | * | 2 | |||||||||
| Klingberg et al. | Sweden | Cross-sectional | * | * | 2 | |||||||||
| Oberoi et al. | USA | Cross-sectional | * | * | 2 | |||||||||
| Ahonen et al. | Finland | Cross-sectional | * | * | * | 3 | ||||||||
| Bruserud et al. | Norway | Cross-sectional | * | * | 2 | |||||||||
| McGovern et al. | Ireland | Cross-sectional | * | * | * | 3 | ||||||||
| Ferre et al. | North/South America | Prospective cohort | * | * | * | 3 | ||||||||
The use of
means that the publication qualified in the respective item of the Newcastle-Ottawa Scale. (1) Criteria. (2) Representativeness of the exposed cohort. (3) Selection of the non-exposed cohort. (4) Ascertainment of exposure. (5) Comparability on the basis of confounding control in the design or analysis. (6) Additional confounding control. (7) Assessment of outcome. (8) Duration of follow-up period.